This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Hepatocellular Carcinoma HCC Treatment Market

Hepatocellular Carcinoma HCC Treatment Market: Global Industry Analysis and Opportunity Assessment 2016-2026

Market Insights on Hepatocellular Carcinoma HCC Treatment covering sales outlook, demand forecast & up-to-date key trends

Hepatocellular Carcinoma HCC Treatment Market Overview

Hepatocellular carcinoma (HCC) is also known as malignant hepatoma. HCC is the major malignancy of the liver and is found to occur mainly in patients with chronic liver diseases and cirrhosis. The cells of origin of HCC are the hepatic stem cells, although this remains the subject of investigation.

The hepatic tumors proliferates with local expansion, spreading in intrahepatic region and finally distant metastases. The uncommon hepatocellular carcinoma is anticipated to witness rise in incidence rate during the forecast period. HCC is currently expected to be the third leading cause of death worldwide.

In the past, HCC generally occurred at an advanced stage of decompensated liver disease or cirrhosis. The technological advancements and the routine liver function tests are now resulting in the early detection of hepatocellular carcinoma. The increase in incidences of hepatocellular carcinoma associated with hepatitis C virus are expected to grow the hepatocellular carcinoma treatment market during the forecast period.

Hepatocellular Carcinoma(HCC) Treatment Market: Drivers and Restraints

The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2015. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury.

The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market.

However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.

Customize this Report

Let us know your requirement to get
100% FREE customization

Hepatocellular Carcinoma(HCC) Treatment Market: Overview

Inventions in technologies for cancer treatment procedures are expected to launch into the market in the forecast period. Moreover, the increasing investment of pharmaceutical companies in the research and development of anticancer drugs would contribute to the growth of hepatocellular carcinoma treatment market.

Monoclonal antibodies and other immunological treatments are generally known for their lesser side effects and better efficacy.

Hepatocellular Carcinoma(HCC) Treatment Market: Regional Overview

Geographically, the global Hepatocellular Carcinoma (HCC) treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East and Africa. Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections are found to be the most significant cause of hepatocellular carcinoma.

Chronic HBV infection is the principal cause of hepatocellular carcinoma in Asia and Africa. HCV infection is the principal cause of hepatocellular carcinoma in North America, Europe, and Japan. The global hepatocellular carcinoma treatment market is expected to grow in future due to increasing investment by multinational companies in the cancer research.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Hepatocellular Carcinoma(HCC) Treatment Market: Key Players

Bayer AG is one of the leading provider of hepatocellular carcinoma (HCC) treatment drugs. Some of the key players in hepatocellular carcinoma treatment market are Novartis Pharmaceuticals, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. These companies focuses on the priority areas of the antiviral and oncology in order to address unmet medical needs.

The report covers exhaustive analysis on

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Hepatocellular Carcinoma(HCC) Treatment Market: Segmentation

The global hepatocellular carcinoma (HCC) treatment market has been segmented on the basis of application, end use and geography.

Based on application, the global hepatocellular carcinoma (HCC) treatment market is segmented into:

  • Brachytherapy
  • Chemotherapy
  • Local Ablation Therapy

Based on end user type, the global hepatocellular carcinoma (HCC) treatment market is segmented into:

  • Hospitals
  • Clinics
  • Cancer rehabilitation centers
Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Hepatocellular Carcinoma HCC Treatment Market